Exploiting GLIOblastoma intractability to address European research TRAINing needs translational brain tumor research, cancer systems medicine and integrative multi-omics

Funding period:

01.09.2017 - 31.08.2021

Project description:

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs.

  1. Royal College of Surgeons in Ireland (RCSI), Dublin (IER)
  2. University of Stuttgart, Stuttgart (DE)
  3. Luxembourg Institute of Health (LIH), Luxembourg (LU)
  4. VIB (VIB), Gent (BE)
  5. Institut du Cerveau et de la Moelle Epiniere (ICM), Paris (F)
  6. Erasmus Universitair Medisch Centrum Rotterdam (EMC), Rotterdam (NL)
  7. Genexplain GmbH (GEX), Wolfenbüttel (DE)
  8. Information Technology for Translational Medicine (ITTM), Esch-sur-Alzette (LU)
  9. Agilent Technologies Belgium NV (AG), Diegem (BE)


This image shows Markus Morrison

Markus Morrison

Prof. Dr.

Director of the Institute

To the top of the page